摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate) | 1355216-14-6

中文名称
——
中文别名
——
英文名称
1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate)
英文别名
[(2S,3S,4R,5R)-3-azido-5-(3-carbamoylpyridin-1-ium-1-yl)-4-hydroxyoxolan-2-yl]methyl butyl phosphate
1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate)化学式
CAS
1355216-14-6
化学式
C15H22N5O7P
mdl
——
分子量
415.343
InChiKey
ZQIAMRXAQDUNTB-RGCMKSIDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    28
  • 可旋转键数:
    10
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    149
  • 氢给体数:
    2
  • 氢受体数:
    9

反应信息

  • 作为产物:
    参考文献:
    名称:
    Studies on the Synthesis of Nicotinamide Nucleoside and Nucleotide Analogues and Their Inhibitions towards CD38 NADase
    摘要:
    Nicotinamide adenine dinucleotide (NAD) analogues inhibit the NADase activity of CD38. In the current study, efficient protocols for the synthesis of substituted-nicotinamide nucleosides and nucleotides were developed. The one-pot phosphorylation esterification strategy provides a convenient way of obtaining nicotinamide nucleoside phosphodiesters from the corresponding nucleosides. Structure activity relationship information revealed that replacement of 3'-hydroxy group with F or N-3 led to the considerably decrease of activity as compared with ara-F NMN. Phosphodiesterification of nicotinamide nucleosides lowers their inhibitory activities in some extent.
    DOI:
    10.3987/com-11-12361
点击查看最新优质反应信息

文献信息

  • Studies on the Synthesis of Nicotinamide Nucleoside and Nucleotide Analogues and Their Inhibitions towards CD38 NADase
    作者:Liangren Zhang、Anna Ka Yee Kwong、Zhenjun Yang、Zhe Chen、Hon Cheung Lee、Lihe Zhang
    DOI:10.3987/com-11-12361
    日期:——
    Nicotinamide adenine dinucleotide (NAD) analogues inhibit the NADase activity of CD38. In the current study, efficient protocols for the synthesis of substituted-nicotinamide nucleosides and nucleotides were developed. The one-pot phosphorylation esterification strategy provides a convenient way of obtaining nicotinamide nucleoside phosphodiesters from the corresponding nucleosides. Structure activity relationship information revealed that replacement of 3'-hydroxy group with F or N-3 led to the considerably decrease of activity as compared with ara-F NMN. Phosphodiesterification of nicotinamide nucleosides lowers their inhibitory activities in some extent.
查看更多

同类化合物

烟酸单核苷酸 β-烟酰胺单核苷酸 3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓 but-3-yn-l-yl (((2R,3S,4R,5R)-5-(3-carbamoylpyridin-l-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) phosphate nicotinamide mononucleotide nicotinate D-ribonucleotide 1,4-dihydronicotinamide adenine dinucleotide α-Nicotinamid-mononucleotid 3-Carbamoyl-1-((2S,3S,4R,5S)-3,4-dihydroxy-5-phosphonooxymethyl-tetrahydro-furan-2-yl)-pyridinium NMNH Nicotinamide-benzimidazole dinucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(2-methoxyphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-(naphthalen-1-ylmethylamino)-5-oxopentyl]triazol-4-yl]ethyl phosphate 2-(1-adamantyl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 2-[1-[5-(benzhydrylamino)-5-oxopentyl]triazol-4-yl]ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-methylphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-phenylethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 5-phenoxypentyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-oxo-5-[(4-phenylphenyl)methylamino]pentyl]triazol-4-yl]ethyl phosphate 2-(1-benzyltriazol-4-yl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-fluorophenoxy)ethoxy]ethyl phosphate butyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 1-(3'-deoxy-3'-fluoro-β-D-xylofuranosyl)nicotinamide-5'-phosphate 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(benzyl phosphate) 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate) [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate beta-Nicotinamide mononucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl hydrogen phosphate 1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2R,3S,4R,5R)-5-(benzimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono phosphate [[(2R,3R,4R,5R)-5-amino-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate 1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [amino-[5-azanidyl-1-[5-[[[[5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxy-3-phosphonooxyoxolan-2-yl]imidazolidine-4,5-diid-4-yl]methyl]azanide [(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid Pyridinium, 3-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-naphthalen-1-yltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methyl hydrogen phosphate β-nicotinamide mononucleotide [(2R,3R,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2S,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [(2S,3S,4S,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid